1. BOLETIN INFORMATIVO GEDEFO


  2. NUMERO 1/2014


  3. INTRODUCCION

Desde el Grupo de Trabajo GEDEFO queremos presentarte este Boletín, que nace con el objetivo de completar la información de nuestra página web. Como sabéis, a finales de Noviembre empezamos nuestra andadura en Twitter con bastante éxito, pero como somos conscientes de que no todo el mundo utiliza las redes sociales, consideramos que sería útil  difundir las aportaciones mas interesantes.

En este primer número hemos recopilado aquellos tuits que nos parecen mas interesantes con los link a los artículos originales.

Esperamos que os resulte interesante esta iniciativa y os animamos a uniros al grupo y participar en él.

 



 

Tweets

  • Selected tweets from yesterday's GICS 2014 w/links. @ASCOGI


  • "No Benefit to Adding Cetuximab in Esophageal Cancer"GICS 2014

  •  

  •   
  • Cervical cancer: the importance of regular screening. ACS.

  •  

  • RAS testing should become the standard of care for identifying who will benefit from anti-EGFR therapy in CRC

  • Capecitabine plus temozolomide may achieve extraordinary responses for patients with neuroendocrine tumors

  • The Global Opioid Policy Initiative project to evaluate the accessibility of opioids for management of cancer pain


  • Is oral chemotherapy prescription safe for patients? A cross-sectional survey vía


  • BJC First-line gefitinib in Caucasian EGFR mutation + NSCLC patients: phase-IV, open-label, single-arm study

    1. Oncology and Hematology Editors Choice: Top Stories of 2013. NEJM watch journal w/article links vía

    1. Dosing Considerations for Obese Patients Receiving Cancer Chemotherapeutic Agents vía

    2. FDA Approves First Combination Therapy for Melanoma http://bit.ly/1fgpRy2

      Retwitteado por GEDEFO
    3. NICE: Prostate cancer: diagnosis and treatment. Clinical guidelines, CG175 - Issued: January 2014 http://guidance.nice.org.uk/CG175

    4. Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion.http://www.ncbi.nlm.nih.gov/pubmed/23512269

    5. Medical Oncology Consultation and Minimization of Overtreatment in Men With Low-Risk Prostate Cancer http://feedly.com/e/ZK9jZkhS vía @feedly

    6. Sunitinib + Prednisone Vs Prednisone Alone in Progressive Castrat-Resist Prostate Cancer (Phase IIITrial) http://feedly.com/e/P-RUMRVB vía @feedly

    7. Central venous catheter-related infection in hematology+oncology: 2012updated guidelines (German Society)vía

    8. From Cochrane: Combination versus sequential single agent chemotherapy for metastatic breast cancer

    9. annual screening for lung cancer with LDCT for high risk pts : final USPSTF Recommendations for Lung Cancer Screening